12/3
11:26 am
ibrx
ImmunityBio (IBRX) Slashes 9% on Lack of Leads [Yahoo! Finance]
Low
Report
ImmunityBio (IBRX) Slashes 9% on Lack of Leads [Yahoo! Finance]
12/3
05:01 am
ibrx
A Second Anktiva Approval Could Be The Catalyst ImmunityBio Needs [Seeking Alpha]
Medium
Report
A Second Anktiva Approval Could Be The Catalyst ImmunityBio Needs [Seeking Alpha]
12/1
02:37 pm
ibrx
A Fresh Look at ImmunityBio (IBRX) Valuation After Recent Share Rally [Yahoo! Finance]
Low
Report
A Fresh Look at ImmunityBio (IBRX) Valuation After Recent Share Rally [Yahoo! Finance]
12/1
09:22 am
ibrx
ImmunityBio (IBRX) Soars 10.8% Ahead of Health Conferences [Yahoo! Finance]
Medium
Report
ImmunityBio (IBRX) Soars 10.8% Ahead of Health Conferences [Yahoo! Finance]
11/30
05:43 am
ibrx
Is ImmunityBio Inc. (IBRX) The Best US Stock To Buy Under $20? [Yahoo! Finance]
Medium
Report
Is ImmunityBio Inc. (IBRX) The Best US Stock To Buy Under $20? [Yahoo! Finance]
11/25
05:48 pm
ibrx
H.C. Wainwright Asserts Buy Rating on Immunitybio Inc. (IBRX) as Net Loss Narrows on Robust Product Revenue [Yahoo! Finance]
Low
Report
H.C. Wainwright Asserts Buy Rating on Immunitybio Inc. (IBRX) as Net Loss Narrows on Robust Product Revenue [Yahoo! Finance]
11/19
12:56 pm
ibrx
A Fresh $16 Million Bet on ImmunityBio: What Investors Should Know [Yahoo! Finance]
Low
Report
A Fresh $16 Million Bet on ImmunityBio: What Investors Should Know [Yahoo! Finance]
11/19
05:18 am
ibrx
ImmunityBio: Checking The Boxes Of A True Commercial-Stage Biotech [Seeking Alpha]
Low
Report
ImmunityBio: Checking The Boxes Of A True Commercial-Stage Biotech [Seeking Alpha]
11/13
01:39 pm
ibrx
ImmunityBio (NASDAQ:IBRX) had its "buy" rating reaffirmed by analysts at D. Boral Capital. They now have a $24.00 price target on the stock.
Low
Report
ImmunityBio (NASDAQ:IBRX) had its "buy" rating reaffirmed by analysts at D. Boral Capital. They now have a $24.00 price target on the stock.
11/13
12:18 pm
ibrx
How ImmunityBio's (IBRX) Revenue Surge and Narrowed Losses May Affect Investor Outlook [Yahoo! Finance]
Low
Report
How ImmunityBio's (IBRX) Revenue Surge and Narrowed Losses May Affect Investor Outlook [Yahoo! Finance]
11/13
09:36 am
ibrx
New Survey Reveals Non-Muscle Invasive Bladder Cancer Patients Seek More Care Conversations [Yahoo! Finance]
Low
Report
New Survey Reveals Non-Muscle Invasive Bladder Cancer Patients Seek More Care Conversations [Yahoo! Finance]
11/13
09:00 am
ibrx
New Survey Reveals Non-Muscle Invasive Bladder Cancer Patients Seek More Care Conversations
Medium
Report
New Survey Reveals Non-Muscle Invasive Bladder Cancer Patients Seek More Care Conversations
11/12
09:56 am
ibrx
enGene Holdings: Still A Buy After A Massive Surge [Seeking Alpha]
Low
Report
enGene Holdings: Still A Buy After A Massive Surge [Seeking Alpha]
11/10
09:18 am
ibrx
Ruder Finn Introduces rf.StoryLab, a Creative Incubator to Unlock the Potential of AI-Driven Storytelling [Yahoo! Finance]
Neutral
Report
Ruder Finn Introduces rf.StoryLab, a Creative Incubator to Unlock the Potential of AI-Driven Storytelling [Yahoo! Finance]
11/5
09:05 am
ibrx
ImmunityBio (NASDAQ:IBRX) had its "buy" rating reaffirmed by analysts at D. Boral Capital. They now have a $24.00 price target on the stock.
Low
Report
ImmunityBio (NASDAQ:IBRX) had its "buy" rating reaffirmed by analysts at D. Boral Capital. They now have a $24.00 price target on the stock.
11/5
12:13 am
ibrx
ImmunityBio GAAP EPS of -$0.07 beats by $0.04, revenue of $32.06M beats by $0.18M [Seeking Alpha]
Medium
Report
ImmunityBio GAAP EPS of -$0.07 beats by $0.04, revenue of $32.06M beats by $0.18M [Seeking Alpha]
11/4
11:04 pm
ibrx
Driven by Strong Demand, ImmunityBio Reports 467% Year-to-Date Unit Growth and $75 Million in Sales Year-to-Date, Up 434% from Q3 2024 [Yahoo! Finance]
Medium
Report
Driven by Strong Demand, ImmunityBio Reports 467% Year-to-Date Unit Growth and $75 Million in Sales Year-to-Date, Up 434% from Q3 2024 [Yahoo! Finance]
11/4
10:12 pm
ibrx
Driven by Strong Demand, ImmunityBio Reports 467% Year-to-Date Unit Growth and $75 Million in Sales Year-to-Date, Up 434% from Q3 2024
Low
Report
Driven by Strong Demand, ImmunityBio Reports 467% Year-to-Date Unit Growth and $75 Million in Sales Year-to-Date, Up 434% from Q3 2024
10/14
12:15 pm
ibrx
ImmunityBio (NASDAQ:IBRX) had its "sell (e+)" rating reaffirmed by analysts at
Weiss Ratings.
Low
Report
ImmunityBio (NASDAQ:IBRX) had its "sell (e+)" rating reaffirmed by analysts at
Weiss Ratings.
10/3
01:25 pm
ibrx
ImmunityBio: A Small Bet Is Warranted [Seeking Alpha]
Low
Report
ImmunityBio: A Small Bet Is Warranted [Seeking Alpha]
9/20
03:08 am
ibrx
ImmunityBio's (IBRX) ANKTIVA Shows Survival Gains in Lung Cancer Patients [Yahoo! Finance]
Low
Report
ImmunityBio's (IBRX) ANKTIVA Shows Survival Gains in Lung Cancer Patients [Yahoo! Finance]
9/10
08:23 am
ibrx
CoRegen, Inc. Strengthens Leadership Team with the Appointments of Sonja Nelson as Chief Financial Officer and Peter Gelinas as Chief Technical Officer [Yahoo! Finance]
Low
Report
CoRegen, Inc. Strengthens Leadership Team with the Appointments of Sonja Nelson as Chief Financial Officer and Peter Gelinas as Chief Technical Officer [Yahoo! Finance]
9/10
08:00 am
ibrx
ImmunityBio (NASDAQ:IBRX) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $8.00 price target on the stock.
Low
Report
ImmunityBio (NASDAQ:IBRX) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $8.00 price target on the stock.
9/8
10:28 am
ibrx
ImmunityBio (NASDAQ:IBRX) had its "buy" rating reaffirmed by analysts at D. Boral Capital. They now have a $24.00 price target on the stock.
Low
Report
ImmunityBio (NASDAQ:IBRX) had its "buy" rating reaffirmed by analysts at D. Boral Capital. They now have a $24.00 price target on the stock.
9/8
08:44 am
ibrx
ImmunityBio's ANKTIVA® Reverses Lymphopenia and Extends Overall Survival in Patients With Advanced Non-Small Cell Lung Cancer Resistant to Checkpoint Therapy [Yahoo! Finance]
Low
Report
ImmunityBio's ANKTIVA® Reverses Lymphopenia and Extends Overall Survival in Patients With Advanced Non-Small Cell Lung Cancer Resistant to Checkpoint Therapy [Yahoo! Finance]